{
    "nct_id": "NCT04186845",
    "official_title": "A Prospective, Phase 3, Multi Center, Single-arm, Imaging Study Investigating the Safety and Diagnostic Performance of rhPSMA 7.3 (18F) PET Ligand in Men With Suspected Prostate Cancer Recurrence Based on Elevated PSA Following Prior Therapy (SPOTLIGHT)",
    "inclusion_criteria": "1. Patient is male and aged >18 years old.\n2. History of localized adenocarcinoma of the prostate with prior curative intent treatment.\n3. An elevated PSA, clinically suspicious for biochemically recurrent disease:\n\n   * Following Radical Prostatectomy: PSA >0.2 ng/mL\n   * Following Radiotherapy: nadir +2 ng/mL.\n4. Potentially eligible for salvage therapy with curative intent.\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "1. Patients who are planned to have an x-ray contrast agent or other PET radiotracer <24 hours prior to the PET scan.\n2. Patients currently receiving Androgen Deprivation Therapy (ADT).",
    "miscellaneous_criteria": ""
}